Clinical evidence and exploratory trial findings
Research findings have been published in Obstetrics & Gynecology and the Journal of Sexual Medicine,2 according to Daré Bioscience. Irwin Goldstein, MD, director of San Diego Sexual Medicine, stated, “As more women speak openly about their sexual health, the need for research-backed solutions has never been greater,” and “Daré’s commitment to both clinical integrity and timely access ensures women who need it don’t have to wait to benefit from this innovation.”
In a phase 2b randomized, placebo-controlled trial enrolling 200 premenopausal women with female sexual arousal disorder, investigators evaluated 3.6% topical sildenafil over 12 weeks. In the intention-to-treat population, improvements in the Arousal Sensation domain of the Sexual Function Questionnaire were greater in the sildenafil arm but did not reach statistical significance versus placebo for the coprimary endpoints. However, exploratory analyses identified a subset of women with female sexual arousal disorder either alone or with decreased desire, who demonstrated significant improvements in sexual arousal sensation and trends toward improvements in desire and orgasm domains, along with reduced sexual distress in selected Female Sexual Distress Scale questions.2
Regulatory status and availability
The product is being provided as a Section 503B compounded drug manufactured under current Good Manufacturing Practice requirements and subject to U.S. Food and Drug Administration inspection. Compounded products are not FDA approved, and the FDA does not evaluate compounded products for safety, effectiveness, or quality. According to the announcement, the company intends to continue activities necessary to seek full FDA approval in the future.
Prescriptions are currently available for pre-order in Connecticut, Florida, Indiana, Missouri, New Hampshire, New Jersey, Oregon, Pennsylvania, Rhode Island, and Utah, with shipments expected within 45 days of order placement. Additional state availability is expected in late 2025 and early 2026.
Market need for female arousal therapies
The company noted that approximately 20 million women in the United States report challenges related to genital arousal and that no FDA-approved therapeutic agents directly target this need. The availability of a clinically evaluated topical sildenafil option may provide a new pathway for women presenting with reduced genital arousal or decreased genital blood flow. The company described the launch as an example of ongoing efforts to narrow treatment disparities in women’s health.
The product will be distributed through Medvantx as part of the DARE Health Hub platform. Additional product information and prescribing logistics are available through the manufacturer’s website, including updates on availability by state.
References
- Dare Biosciences. DARE to PLAY™ Sildenafil Cream Now Available for Pre-Order by Prescription: First Evidence-Based Topical Arousal Cream for Women Begins Commercial Rollout in Select States via 503B Outsourcing Facility. Dare Biosciences. December 10, 2025. Accessed December 10, 2025. https://ir.darebioscience.com/news-releases/news-release-details/dare-playtm-sildenafil-cream-now-available-pre-order
- Johnson I, Thurman AR, Cornell KA, et al. Preliminary Efficacy of Topical Sildenafil Cream for the Treatment of Female Sexual Arousal Disorder: A Randomized Controlled Trial. Obstet Gynecol. 2024;144(2):144-152. doi:10.1097/AOG.0000000000005648